title: Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients.
abstract: BACKGROUND
  We compared the efficacy of two neuroleptics with different receptor profiles (zuclopenthixol and haloperidol) in learning disabled patients with behavioural disturbance.
  
  
  METHODS
  A double-blind crossover study (2 x 8 weeks; n = 34), interrupted by a two-week single-blind washout period, was employed. Assessments included the Schedule for Handicaps, Behaviour, and Skills (SHBS) and Clinical Global Impression (CGI).
  
  
  RESULTS
  The SHBS score was significantly reduced for the zuclopenthixol cohort only. End-point analysis between the two drugs also showed an enhanced effect for zuclopenthixol over haloperidol. CGI scores did not reveal significant differences between the two drugs.
  
  
  CONCLUSIONS
  Zuclopenthixol may be superior to haloperidol for the treatment of behavioural disturbances in mentally retarded subjects.
authors.affiliation: University of Oslo, Department of Psychosomatic and Behavioural Medicine, National Hospital, Norway.
authors.forename: U F
authors.initials: UF
authors.lastname: Malt
authors.forename: R
authors.initials: R
authors.lastname: Nystad
authors.forename: T
authors.initials: T
authors.lastname: Bache
authors.forename: O
authors.initials: O
authors.lastname: Noren
authors.forename: M
authors.initials: M
authors.lastname: Sjaastad
authors.forename: K O
authors.initials: KO
authors.lastname: Solberg
authors.forename: S
authors.initials: S
authors.lastname: Tønseth
authors.forename: P
authors.initials: P
authors.lastname: Zachariassen
authors.forename: E
authors.initials: E
authors.lastname: Maehlum
mesh_terms: D000328:Adult; D001521:Behavior Therapy; D003006:Clopenthixol / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy* / Q000523:psychology; D007859:Learning Disabilities / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D012920:Social Behavior Disorders / Q000188:drug therapy* / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D003006:Clopenthixol; D006220:Haloperidol